| Gene symbol | MSLN | Synonyms | MPF, SMRP | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | mesothelin | ||||
| GTO ID | GTC3596 |
| Trial ID | NCT06051695 |
| Disease | Colorectal Cancer | Non Small Cell Lung Cancer | Pancreas Cancer | Colon Cancer | Rectal Cancer | Ovarian Cancer | Mesothelioma | Lung Cancer |
| Altered gene | MSLN |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | A2B694 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression |
| Year | 2024 |
| Country | United States |
| Company sponsor | A2 Biotherapeutics Inc. |
| Other ID(s) | A2B694-101 |
| Cohort 1 | |||||||||
|
|||||||||